The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Cornerstone Therapeutics' revenue will wither 32.8% and EPS will shrink to a loss.
The average estimate for revenue is $18.8 million. On the bottom line, the average EPS estimate is -$0.02.
Last quarter, Cornerstone Therapeutics logged revenue of $22.2 million. GAAP reported sales were 26% lower than the prior-year quarter's $30.0 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.05. GAAP EPS were -$0.07 for Q1 compared to $0.07 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 60.8%, 570 basis points worse than the prior-year quarter. Operating margin was -20.5%, 2,900 basis points worse than the prior-year quarter. Net margin was -8.2%, 1,400 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $80.1 million. The average EPS estimate is $0.10.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 107 members out of 111 rating the stock outperform, and four members rating it underperform. Among 19 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 18 give Cornerstone Therapeutics a green thumbs-up, and one gives it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Cornerstone Therapeutics is buy, with an average price target of $12.00.
Over the decades, small-cap stocks like Cornerstone Therapeutics have provided market-beating returns, provided they're value-priced and have solid businesses. Read about a pair of companies with a lock on their markets in "Too Small to Fail: 2 Small Caps the Government Won't Let Go Broke." Click here for instant access to this free report.
- Add Cornerstone Therapeutics to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.